We showed some activities of I3C and genistein are blocked or partially reversed by inhibition of BRCA1: (1) upregulation of BRCA2 by I3C or genistein; (2) cytotoxicity due to high doses of I3C; (3) inhibition of E2-stimulated ER-α activity by I3C and/or genistein in breast cancer cells; and (4) inhibition of DHT-stimulated AR activity by I3C and genistein in prostate cancer cells. Here, BRCA2 is linked to prostate carcinoma.